Keywords
chronic vein disease, type 2 diabetes, phlebotropic therapy, preparations of micronized purified flavonoid fraction, α-lipoic acid.
How to Cite
Zhuravlyova, L., & Filonenko, M. (2020). A comprehensive approach to phlebotropic therapy in patients with type 2 diabetes mellitus. The Practitioner, (2), 56-60. Retrieved from https://plr.com.ua/index.php/journal/article/view/594
Abstract
Diabetes mellitus and chronic venous insufficiency are common diseases of the adult population of economically developed countries. Current knowledge allows us to identify several priority strategies and goals aimed at correcting the main pathophysiological mechanisms of development and progression of chronic venous insufficiency in patients with type 2 diabetes. In particular, the use of venoactive drugs, whose role in increasing the tone and contractility of veins, reducing inflammation and edema, as well as improving microcirculation and accelerating healing of venous ulcers has been carefully studied and successfully implemented in clinical practice. An additional drug that improves microcirculatory blood flow in the lower extremities and also reduces the symptoms of diabetic
polyneuropathy and chronic venous insufficiency in patients with combined pathology is α-lipoic acid.
References
1. Rabe E., Berboth G., Pannier F. Epidemiology of chronic venous diseases // Wien Med. Wochenschr. — 2016.—166 (9-10). — P. 260-3. doi: 10.1007/s10354-016-0465-y.
2. Eberhardt R.T., Raffetto J.D. Chronic venous insufficiency // Circulation. — 2014. — 130. — P. 333-346. doi: 10.1161 / circulationaha.113.006898.
3. Синяченко Ю.О., Самойленко Г.Е., Синяченко О.В. Течение и эффективность лечения варикозной болезни вен нижних конечностей у больных сахарным диабетом // Mezhdunarodnyi Endokrinologicheskii Zhurnal. — 2017. — 13. — P. 27-32. doi: 10.22141/2224-0721.13.1.2017.96752.
4. Davies A.H. The Seriousness of Chronic Venous Disease: A Review of Real-World Evidence // Adv. Ther. — 2019. — 36. — P. 5-12. https://doi.org/10.1007/s12325-019-0881-7
5. Papanas N., Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy // Expert Opin Pharmacother. — 2014 Dec. — 15 (18). — P. 2721-2731.
6. Сarpentier P.H., Maricq H.R., Biro C., et al. Prevalence, risk factors, and clinical patterns of chronic venous disorders of lower limbs: a population-based study in France // J. Vasc. Surg. — 2004. — 40. — P. 650-659. doi: 10.1016 / j.jvs.2004.07.025.
7. Mansilha A., Sousa J. Pathophysiological Mechanisms of Chronic Venous Disease and Implications for Venoactive Drug Therapy // International journal of molecular sciences. — 2018 Jun. — 19 (6). — P. 1669-1682. doi: 10.3390/ijms19061669.
8. Lane T.R., Sritharan K., Herbert J.R., Franklin I.J., Davies A.H. Management of chronic venous disease by primary care // Phlebology. — 2013. — 28 (6). — P. 299-304.
9. Maggioli A. Chronic venous disorders: pharmacological and clinical aspects of micronized purified flavonoid fraction // Phlebolymphology. — 2016. — 23. — P. 82-89.
10. Martinez‐Zapata M.J., Vernooij R.W.M., Uriona Tuma S.M., Stein A.T., Moreno R.M., Vargas E., Capellà D., Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database of Systematic Reviews. — 2016, Issue 4. Art. No.: CD003229. DOI: 10.1002/14651858.CD003229.pub3.
11. Каменская О.В., Марченко Е.В. Применение детралекса для коррекции нарушений гемолимфоциркуляции у пожилых больных с синдромом диабетической стопы на фоне инсулиннезависимого сахарного диабета // Современные проблемы науки и образования. — 2008. — 1. — C. 141-142.
12. Savineau J.P., Marthan R. Diosmin-induced increase in sensitivity to Ca2+ of the smooth muscle contractile apparatus in the rat isolated femoral vein // Br. J. Pharmacol. — 2004. — 111. — P. 978-980. doi: 10.1111 / j.1476-5381.1994.tb14838.x. 68.
13. Juteau N., Bakri F., Pomies J., et al. The human saphenous vein in pharmacology: effect of a new micronized flavonoid fraction (daflon 500 mg) on norepinephrine induced contraction // Int. Angiol. — 2005. — 14. — P. 8-13.
14. Pascarella L., Lulic D., Penn A.H., et al. Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg // Eur. J. Vasc. Endovasc. Surg. — 2008. — 35. — P. 102-110. doi: 10.1016 / j. ejvs.2007.08.011.
15. Bush R., et al. Recommendations for the medical management of chronic venous disease: the role of micronized purified Flavanoid Fraction (mpFF) // Phlebology. — 2017. — 32. — P. 3-19. doi: 10.1177 / 0268355517692221.
2. Eberhardt R.T., Raffetto J.D. Chronic venous insufficiency // Circulation. — 2014. — 130. — P. 333-346. doi: 10.1161 / circulationaha.113.006898.
3. Синяченко Ю.О., Самойленко Г.Е., Синяченко О.В. Течение и эффективность лечения варикозной болезни вен нижних конечностей у больных сахарным диабетом // Mezhdunarodnyi Endokrinologicheskii Zhurnal. — 2017. — 13. — P. 27-32. doi: 10.22141/2224-0721.13.1.2017.96752.
4. Davies A.H. The Seriousness of Chronic Venous Disease: A Review of Real-World Evidence // Adv. Ther. — 2019. — 36. — P. 5-12. https://doi.org/10.1007/s12325-019-0881-7
5. Papanas N., Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy // Expert Opin Pharmacother. — 2014 Dec. — 15 (18). — P. 2721-2731.
6. Сarpentier P.H., Maricq H.R., Biro C., et al. Prevalence, risk factors, and clinical patterns of chronic venous disorders of lower limbs: a population-based study in France // J. Vasc. Surg. — 2004. — 40. — P. 650-659. doi: 10.1016 / j.jvs.2004.07.025.
7. Mansilha A., Sousa J. Pathophysiological Mechanisms of Chronic Venous Disease and Implications for Venoactive Drug Therapy // International journal of molecular sciences. — 2018 Jun. — 19 (6). — P. 1669-1682. doi: 10.3390/ijms19061669.
8. Lane T.R., Sritharan K., Herbert J.R., Franklin I.J., Davies A.H. Management of chronic venous disease by primary care // Phlebology. — 2013. — 28 (6). — P. 299-304.
9. Maggioli A. Chronic venous disorders: pharmacological and clinical aspects of micronized purified flavonoid fraction // Phlebolymphology. — 2016. — 23. — P. 82-89.
10. Martinez‐Zapata M.J., Vernooij R.W.M., Uriona Tuma S.M., Stein A.T., Moreno R.M., Vargas E., Capellà D., Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database of Systematic Reviews. — 2016, Issue 4. Art. No.: CD003229. DOI: 10.1002/14651858.CD003229.pub3.
11. Каменская О.В., Марченко Е.В. Применение детралекса для коррекции нарушений гемолимфоциркуляции у пожилых больных с синдромом диабетической стопы на фоне инсулиннезависимого сахарного диабета // Современные проблемы науки и образования. — 2008. — 1. — C. 141-142.
12. Savineau J.P., Marthan R. Diosmin-induced increase in sensitivity to Ca2+ of the smooth muscle contractile apparatus in the rat isolated femoral vein // Br. J. Pharmacol. — 2004. — 111. — P. 978-980. doi: 10.1111 / j.1476-5381.1994.tb14838.x. 68.
13. Juteau N., Bakri F., Pomies J., et al. The human saphenous vein in pharmacology: effect of a new micronized flavonoid fraction (daflon 500 mg) on norepinephrine induced contraction // Int. Angiol. — 2005. — 14. — P. 8-13.
14. Pascarella L., Lulic D., Penn A.H., et al. Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg // Eur. J. Vasc. Endovasc. Surg. — 2008. — 35. — P. 102-110. doi: 10.1016 / j. ejvs.2007.08.011.
15. Bush R., et al. Recommendations for the medical management of chronic venous disease: the role of micronized purified Flavanoid Fraction (mpFF) // Phlebology. — 2017. — 32. — P. 3-19. doi: 10.1177 / 0268355517692221.
Downloads
Download data is not yet available.